BACKGROUND: Naturally occurring, thymic-derived Foxp3+CD25+CD4+ regulatory T cells (nTregs) are pivotal for the maintenance of self-tolerance. nTregs, however, are sparse and lack alloantigen specificity, and these properties pose challenges for their use in clinical transplantation. METHODS: We established mixed leukocyte reaction (MLR) with dendritic cells (DCs) as stimulators and CD4+ T cells as responders and supplemented the MLR with IL-2 and TGF-β1 and investigated whether DCs+IL-2+TGF-β1 differentiate the polyclonal CD4+ cells into alloantigen-specific and allograft protective Tregs. RESULTS: We found a greater than a 10-fold increase in Foxp3+CD25+ subpopulation (P<0.01) following stimulation of BALB/c CD4+ cells with C57BL/6 (B6) CD11c+ DCs+IL-2+TGF-β1 in the MLR. Levels of TGF-β1 messenger RNA (mRNA) (P=0.01) and the ratios of TGF-β1 mRNA to granzyme B mRNA (P=0.0003) and Foxp3 mRNA to granzyme B mRNA (P<0.01) were higher in alloantigen-induced Tregs (alloTregs) compared with nTregs. alloTregs suppressed MLR at a 16:1 responder to suppressor ratio, whereas nTregs suppressed at 4:1. Suppression by alloTregs was alloantigen specific and was observed at the level of responder cells and at the level of stimulator cells. In a fully H-2-mismatched, nonlymphopenic, immunocompetent mouse islet transplantation model, alloTregs but not nTregs prolonged survival of islet allografts without any other immunosuppressive therapy (P=0.0003), and the protection was alloantigen specific. CONCLUSIONS: A combination of CD11c+ DCs, IL-2, and TGF-β1 may help differentiate naive, high abundant CD4+ T into alloantigen-specific and allograft protective Foxp3+Tregs.
BACKGROUND: Naturally occurring, thymic-derived Foxp3+CD25+CD4+ regulatory T cells (nTregs) are pivotal for the maintenance of self-tolerance. nTregs, however, are sparse and lack alloantigen specificity, and these properties pose challenges for their use in clinical transplantation. METHODS: We established mixed leukocyte reaction (MLR) with dendritic cells (DCs) as stimulators and CD4+ T cells as responders and supplemented the MLR with IL-2 and TGF-β1 and investigated whether DCs+IL-2+TGF-β1 differentiate the polyclonal CD4+ cells into alloantigen-specific and allograft protective Tregs. RESULTS: We found a greater than a 10-fold increase in Foxp3+CD25+ subpopulation (P<0.01) following stimulation of BALB/c CD4+ cells with C57BL/6 (B6) CD11c+ DCs+IL-2+TGF-β1 in the MLR. Levels of TGF-β1 messenger RNA (mRNA) (P=0.01) and the ratios of TGF-β1 mRNA to granzyme B mRNA (P=0.0003) and Foxp3 mRNA to granzyme B mRNA (P<0.01) were higher in alloantigen-induced Tregs (alloTregs) compared with nTregs. alloTregs suppressed MLR at a 16:1 responder to suppressor ratio, whereas nTregs suppressed at 4:1. Suppression by alloTregs was alloantigen specific and was observed at the level of responder cells and at the level of stimulator cells. In a fully H-2-mismatched, nonlymphopenic, immunocompetent mouse islet transplantation model, alloTregs but not nTregs prolonged survival of islet allografts without any other immunosuppressive therapy (P=0.0003), and the protection was alloantigen specific. CONCLUSIONS: A combination of CD11c+ DCs, IL-2, and TGF-β1 may help differentiate naive, high abundant CD4+ T into alloantigen-specific and allograft protective Foxp3+Tregs.
Authors: Xin Xiao Zheng; Alberto Sánchez-Fueyo; Masayuki Sho; Christoph Domenig; Mohamed H Sayegh; Terry B Strom Journal: Immunity Date: 2003-10 Impact factor: 31.745
Authors: Thangamani Muthukumar; Darshana Dadhania; Ruchuang Ding; Catherine Snopkowski; Rubina Naqvi; Jun B Lee; Choli Hartono; Baogui Li; Vijay K Sharma; Surya V Seshan; Sandip Kapur; Wayne W Hancock; Joseph E Schwartz; Manikkam Suthanthiran Journal: N Engl J Med Date: 2005-12-01 Impact factor: 91.245
Authors: Sayuri Yamazaki; Munjal Patel; Alice Harper; Anthony Bonito; Hidehiro Fukuyama; Maggi Pack; Kristin V Tarbell; Mia Talmor; Jeffrey V Ravetch; Kayo Inaba; Ralph M Steinman Journal: Proc Natl Acad Sci U S A Date: 2006-02-10 Impact factor: 11.205
Authors: Jamal S Lewis; Natalia V Dolgova; Ying Zhang; Chang Qing Xia; Clive H Wasserfall; Mark A Atkinson; Michael J Clare-Salzler; Benjamin G Keselowsky Journal: Clin Immunol Date: 2015-04-02 Impact factor: 3.969
Authors: Jamal S Lewis; Chris Roche; Ying Zhang; Todd M Brusko; Clive H Wasserfall; Mark Atkinson; Michael J Clare-Salzler; Benjamin G Keselowsky Journal: J Mater Chem B Date: 2014-05-07 Impact factor: 6.331
Authors: Eirini Nikolouli; Matthias Hardtke-Wolenski; Martin Hapke; Michael Beckstette; Robert Geffers; Stefan Floess; Elmar Jaeckel; Jochen Huehn Journal: Front Immunol Date: 2017-06-28 Impact factor: 7.561